Share Price | Sarda Proteins Ltd Stock Analysis & Recommendation

Q: Is Sarda Proteins overvalued or undervalued?

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

Q: What is the technical trend for Sarda Proteins?

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.

Q: How has been the historical performance of Sarda Proteins?

Answer:The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.Breakdown:Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

Q: When is the next results date for Sarda Proteins Ltd?

The next results date for Sarda Proteins Ltd is scheduled for April 30, 2026.

Q: Should I buy, sell or hold Sarda Proteins Ltd?

Based on the current financial situation of Sarda Proteins Ltd, it is advisable to consider a strong sell position. The company has demonstrated weak long-term fundamental strength, with a significant decline in operating profits at a -21.93% CAGR over the past five years. Additionally, the company's ability to service its debt is concerning, highlighted by a poor EBIT to Interest ratio of -0.02. The return on equity is also low at an average of 3.91%, indicating limited profitability relative to shareholders' funds. Recent results show a drastic drop in net sales, with a -78.50% growth over the last nine months, further emphasizing the company's struggles. Moreover, the negative EBITDA of Rs. -0.42 crore and a 56% decline in profits over the past year add to the risk associated with this stock, which is trading at risky levels compared to its historical valuations. With the majority of shareholders being non-institutional, this may also affect the stock's stability and investor confidence.Given these factors, it would be prudent to sell or avoid investing in Sarda Proteins Ltd at this time.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

17 (129.73%) Volume

Shareholding (Apr 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

0.00%

Is Sarda Proteins overvalued or undervalued?

09-Jun-2025

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

View full answer

What is the technical trend for Sarda Proteins?

09-Jun-2025

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

View full answer

How has been the historical performance of Sarda Proteins?

01-Dec-2025

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

View full answer

When is the next results date for Sarda Proteins Ltd?

29-Apr-2026

The next results date for Sarda Proteins Ltd is April 30, 2026.

View full answer

Should I buy, sell or hold Sarda Proteins Ltd?

01-May-2026

Why is Sarda Proteins Ltd falling/rising?

03-Jun-2026

As of 02-Jun, Sarda Proteins Ltd's stock price is stable at 88.70, with a 5.00% increase over the past month and a 19.69% rise year-to-date, outperforming the Sensex. Despite some trading concerns, the stock shows strong historical performance and is above its moving averages, indicating a generally positive outlook.

View full answer

Which are the latest news on Sarda Proteins?

03-Jun-2026

Sarda Proteins Ltd is Rated Strong Sell
Sarda Proteins Ltd is Rated Strong Sell

Compare Sarda Proteins with Similar Stocks

Prime Industries Raj Oil Mills Ambar Protein

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 4.20%

Poor long term growth as Net Sales has grown by an annual rate of 4.87% and Operating profit at 2.29% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.07

With ROE of 20.9, it has a Very Expensive valuation with a 26.5 Price to Book Value

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Edible Oil

Market cap

INR 80 Cr (Micro Cap)

P/E

126.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-2.44

Return on Equity

20.93%

Price to Book

26.45

Revenue and Profits:

Net Sales:

1 Cr

(Quarterly Results - Mar 2026)

Net Profit:

1 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

28.55%

6 Months

10.6%

1 Year

0.0%

2 Years

0.0%

3 Years

73.92%

4 Years

270.35%

5 Years

157.47%

Sarda Proteins for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Sarda Proteins Ltd is Rated Strong Sell

Sarda Proteins Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Sarda Proteins Ltd is Rated Strong Sell

Sarda Proteins Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Sarda Proteins Ltd Valuation Shifts Signal Heightened Risk Amid Strong Sell Rating

Sarda Proteins Ltd, a micro-cap player in the edible oil sector, has witnessed a significant shift in its valuation parameters, prompting a reassessment of its price attractiveness. Despite a robust five-year return of 350.56%, the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios have surged to levels that challenge traditional valuation norms, raising concerns among investors and analysts alike.

Read full news article

Announcements

Board Meeting Outcome for Results - March 2026

30-Apr-2026 | Source : BSE

Results - Standalone Audited Financial results for the quater and financial year ended on 31st March 2026.

Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Thursday 30Th April 2026 To Consider And Approve Standalone Audited Financial Results For The Quarter And Year Ended 31St March 2026

28-Apr-2026 | Source : BSE

Sarda Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 inter alia to consider and approve standalone Audited financial results for the quarter and year ended 31st march 2026

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

15-Apr-2026 | Source : BSE

Certificate under 74(5) for the quarter ended on 31st March 2026.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

4.87%

EBIT Growth (5y)

2.29%

EBIT to Interest (avg)

0.07

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-2.44

Sales to Capital Employed (avg)

5.16

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

-2.02%

ROE (avg)

8.81%

Valuation key factors

Factor

Value

P/E Ratio

126

Industry P/E

Price to Book Value

26.45

EV to EBIT

72.27

EV to EBITDA

72.27

EV to Capital Employed

-16.65

EV to Sales

4.47

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

20.93%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Apr 2026

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Ritika Vegetable Oil Private Limited (0.0%)

Highest Public shareholder

Onix Renewable Limited (77.99%)

Individual Investors Holdings

20.31%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 160.00% vs -94.19% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 800.00% vs -130.00% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.65",
          "val2": "0.25",
          "chgp": "160.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.60",
          "val2": "-0.12",
          "chgp": "600.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.84",
          "val2": "-0.12",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "92.31%",
          "val2": "-48.00%",
          "chgp": "140.31%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.26",
          "val2": "0.14",
          "chgp": "10,800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.19",
          "val2": "0.02",
          "chgp": "-1,050.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.09",
          "val2": "0.03",
          "chgp": "-400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.25%",
          "val2": "14.29%",
          "chgp": "-15.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -35.88% vs 1,850.81% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -261.54% vs 0.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.51",
          "val2": "24.19",
          "chgp": "-35.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.31",
          "val2": "0.12",
          "chgp": "-358.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.21",
          "val2": "0.13",
          "chgp": "-261.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.00%",
          "val2": "0.50%",
          "chgp": "-2.50%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is -33.20% vs 1,760.77% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 6,300.00% vs -50.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.16",
          "val2": "24.19",
          "chgp": "-33.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.29",
          "val2": "0.02",
          "chgp": "1,350.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.64",
          "val2": "0.01",
          "chgp": "6,300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "1.79%",
          "val2": "0.08%",
          "chgp": "1.71%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.65

0.25

160.00%

Operating Profit (PBDIT) excl Other Income

0.60

-0.12

600.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

0.84

-0.12

800.00%

Operating Profit Margin (Excl OI)

92.31%

-48.00%

140.31%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 160.00% vs -94.19% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 800.00% vs -130.00% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

15.26

0.14

10,800.00%

Operating Profit (PBDIT) excl Other Income

-0.19

0.02

-1,050.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.09

0.03

-400.00%

Operating Profit Margin (Excl OI)

-1.25%

14.29%

-15.54%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024

Standalone Net Profit

Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

15.51

24.19

-35.88%

Operating Profit (PBDIT) excl Other Income

-0.31

0.12

-358.33%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.21

0.13

-261.54%

Operating Profit Margin (Excl OI)

-2.00%

0.50%

-2.50%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2025 is -35.88% vs 1,850.81% in Dec 2024

Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -261.54% vs 0.00% in Dec 2024

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

16.16

24.19

-33.20%

Operating Profit (PBDIT) excl Other Income

0.29

0.02

1,350.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

0.64

0.01

6,300.00%

Operating Profit Margin (Excl OI)

1.79%

0.08%

1.71%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is -33.20% vs 1,760.77% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 6,300.00% vs -50.00% in Mar 2025

All Annual Results

Company CV

About Sarda Proteins Ltd

Sarda Proteins Ltd

Micro Cap

Edible Oil

Sarda Proteins Limited was incorporated on December 03, 1991. The Company is mainly engaged in trading of Edible Oils and Agri Commodities, which includes wheat, Oil Seeds, Grains, Edible Oil, etc. The management of the Company was duly changed in FY 2018-19, pursuant to completion of acquisition process by Ritika Vegetable Oil Private Limited as per Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Company Coordinates

Company Details

B-536-537, Matsya Industrial Area Alwar Rajasthan : 301030

Tel: 91-144-2881392

http://www.sardaproteins.com

sardaproteins@yahoo.com

Registrar Details

Link Intime India Pvt Ltd., Narang Tower 44, Community Centre, Naraina Industrial Area , Phase - 1, New Delhi